Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: Assessment of anxiety, depression, and perception of health

Genetics in Medicine

Volumn 7, Issue 8, 2005, Pages 550-556

  Patch, Christine ^a,b   Roderick, Paul ^a   Rosenberg, William ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Hemochromatosis; Psychologic effects; Screening

Indexed keywords

ADULT; ANXIETY; ARTICLE; ATTITUDE; DEPRESSION; DISABLED PERSON; EMPIRICISM; FEMALE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEALTH STATUS; HEMOCHROMATOSIS; HUMAN; MALE; MASS SCREENING; MEDICAL PRACTICE; PHENOTYPE; PSYCHOLOGICAL ASPECT; RATING SCALE; SELF EVALUATION; STATISTICAL SIGNIFICANCE; UNEMPLOYMENT;

ADULT; AGED; ANXIETY; ATTITUDE TO HEALTH; DEPRESSION; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HUMANS; MIDDLE AGED; PHENOTYPE; POPULATION SURVEILLANCE;

EID: 27644476215     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000182466.87113.ce     Document Type: Article

References (29)

1. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 2001;285(5):540-544.
2. Burke W, Thomson E, Khoury MJ, McDonnell SM, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. J Am Med Assoc 1998;280(2):172-178.
3. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med 1999;16(2):134-140.
4. McCullen MA, Crawford DHG, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002;315:169-186.
5. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245(2):139-200.
6. Burke W, Atkins D, Gwinn M, Guttmacher A, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156(4):311-318.
7. National Screening Committee. Second Report of the UK National Screening Committee. London: Department of Health; 2000.
8. Ayme S, Bobrow M, Coviello D, Evers-Kiebooms G, et al. Population genetic screening programmes: proposed recommendations of the European Society of Hum Genet. Eur J Hum Genet 2000;8(12):998-1000.
9. Nuffield Council on Bioethics. Genetic Screening: Ethical Issues. London: Nuffield Council on Bioethics; 1993.
10. World Health Organisation. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetics Services. Geneva: World Health Organization; 1998.
11. Almqvist EW, Bloch M, Brinkman R, Craufurd D, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999;64(5):1293-1304.
12. Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet 2003;64(4):300-309.
13. Meiser B, Butow P, Friedlander M, Barratt A, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer 2002;38(15):2025-2031.
14. Patch C, Roderick P, Rosenberg W. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. J Hepatol 2005;43:149-155.
15. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, et al. Framework for design and evaluation of complex interventions to improve health. BMJ 2000;321(7262):694-696.
16. Fitzpatrick R. Measurement issues in health-related quality of life: challenges for health psychology. Psychol Health 2000;15(1):99-108.
17. Marteau TM, Bekker H. The development of a 6-item short form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31:301-306.
18. Zigmond AS, Snaith P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983;67:361-370.
19. McHorney CA, Ware JE, Raczek AE. The MOS 36 item short form health survey (SF-36) psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263.
20. Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123-1124.
21. Timman R, Stinjen T, Tibben A. Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review. J Med Genet 2004;41:e100.
22. Census dissemination unit. Census knowledge base. Office of National Statistics. Available at: http://www.census.ac.uk/cdu/. Accessed April 21, 2005.
23. Phillimore P, Beattie A, Townsend P. Widening inequality of health in northern England, 1981-91. BMJ 1994;308:1125-1128.
24. Jones B, Jarvis P, Lewis JA, Ebbutt AF. (1996). Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-39.
25. Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet 2001;106(3):233-240.
26. Green MJ, Botkin JR. "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003;138(7):571-575.
27. Van Maarle MC, Stouthard ME, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 2003;40(1):E3.
28. Hicken BL, Calhoun DA, Barton JC, Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test 2004;8(2):90-97.
29. Dooley D, Fielding J, Levi L. Health and unemployment. Ann Rev Public Health 1996;17:449-465.